Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE000STRA555
Wed, 17.05.2023
STRATEC SE
STRATEC’S ANNUAL GENERAL MEETING APPROVES FURTHER DIVIDEND INCREASE: DISTRIBUTION RISES TO € 0.97 PER SHARE
Birkenfeld, May 17, 2023
Shareholders at today’s Annual General Meeting of STRATEC SE (Frankfurt: SBS; Prime Standard, SDAX) approved all agenda items submitted for resolution with clear majorities. As in the past three years, the Annual G [ … ]
Fri, 28.04.2023
STRATEC SE
STRATEC POSTS RESULTS FOR FIRST QUARTER OF 2023 AND CONFIRMS FINANCIAL GUIDANCE
Sales in Q1/2023 -19.8% to € 60.5 million; constant-currency -20.7% (Q1/2022: € 75.4 million)
Adjusted EBIT margin of 6.3% in Q1/2023 as expected below previous year (Q1/2022: 19.9%)
2023 guidance confirmed: Constant-currency sales growth of 8.0% to 12.0% and adjuste [ … ]
Fri, 28.04.2023
STRATEC SE
STRATEC POSTS RESULTS FOR FIRST QUARTER OF 2023 AND CONFIRMS FINANCIAL GUIDANCE
Sales in Q1/2023 -19.8% to € 60.5 million; constant-currency -20.7% (Q1/2022: € 75.4 million)
Adjusted EBIT margin of 6.3% in Q1/2023 as expected below previous year (Q1/2022: 19.9%)
2023 guidance confirmed: Constant-currency sales growth of 8.0% to 12.0% and adjuste [ … ]
Thu, 30.03.2023
STRATEC SE
STRATEC REPORTS FINAL FIGURES FOR 2022 FINANCIAL YEAR
Consolidated sales in 2022 -4.4% to € 274.6 million (2021: € 287.3 million);
constant-currency: -8.3%
Adjusted EBIT margin of 16.4% (2021: 18.9%) broadly in line with original expectations
Major product launch for one of the market leaders in molecular diagnostics and
a well-stocked develo [ … ]
Thu, 30.03.2023
STRATEC SE
STRATEC REPORTS FINAL FIGURES FOR 2022 FINANCIAL YEAR
Consolidated sales in 2022 -4.4% to € 274.6 million (2021: € 287.3 million);
constant-currency: -8.3%
Adjusted EBIT margin of 16.4% (2021: 18.9%) broadly in line with original expectations
Major product launch for one of the market leaders in molecular diagnostics and
a well-stocked develo [ … ]
Thu, 15.12.2022
STRATEC SE
STRATEC TO PARTICIPATE IN THE 41ST ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
Birkenfeld, December 15, 2022
STRATEC SE, Birkenfeld, Germany, (Frankfurt: SBS; Prime Standard, SDAX) will participate in the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at the Westin St. Francis in San Francisco, CA, USA. Marcus Wolfing [ … ]
Thu, 15.12.2022
STRATEC SE
STRATEC TO PARTICIPATE IN THE 41ST ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
Birkenfeld, December 15, 2022
STRATEC SE, Birkenfeld, Germany, (Frankfurt: SBS; Prime Standard, SDAX) will participate in the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at the Westin St. Francis in San Francisco, CA, USA. Marcus Wolfing [ … ]
Thu, 01.12.2022
STRATEC SE
NEW APPOINTMENT TO BOARD OF MANAGEMENT OF STRATEC SE
Birkenfeld, December 1, 2022
The Supervisory Board of STRATEC SE, Birkenfeld, Germany, (Frankfurt: SBS; Prime Standard, SDAX) has decided to extend the company’s Board of Management with a further member and appointed Dr. Georg Bauer to the Board with responsibility for sales as of January 1, [ … ]
Thu, 01.12.2022
STRATEC SE
NEW APPOINTMENT TO BOARD OF MANAGEMENT OF STRATEC SE
Birkenfeld, December 1, 2022
The Supervisory Board of STRATEC SE, Birkenfeld, Germany, (Frankfurt: SBS; Prime Standard, SDAX) has decided to extend the company’s Board of Management with a further member and appointed Dr. Georg Bauer to the Board with responsibility for sales as of January 1, [ … ]
Thu, 03.11.2022
STRATEC SE
STRATEC REPORTS RESULTS FOR FIRST NINE MONTHS OF 2022
Sales in 9M/2022 -7.9% to € 207.7 million (9M/2021: € 225.4 million); constant currency: -11.7%
Adjusted EBIT of € 38.1 million in 9M/2022 (9M/2021: € 48.7 million)
Adjusted EBIT margin of 18.3% (9M/2021: 21.6%) at upper end of target corridor communicated for full year
Significant product [ … ]